This workshop brought together experts using different animal models of lung pathology, letting them interact with young researchers in the field. Through a combination of lectures and group discussions on selected topics gave researchers better access to related technology and experience.
The purpose of this exercise was to generate synergy from the combined experience, which should lead towards:
- Consensus protocols for the study of lung disease in animal models
- An investigation of common mechanisms in different forms of chronic lung disease
- Novel and combined approaches in the field of experimental lung disease
Cystic Fibrosis Lung disease, from animal models to experimental therapeutics. B. Scholte (Rotterdam, The Netherlands)
| |
A Transcriptional Network Controlling Normal Goblet Cell Differentiation and Mucous Production J. Whitsett (Cincinnati, Oh, United States of America)
| |
Chronic epithelial injury in Diffuse Parenchymal Lung Diseases (DPLD) cellular consequences and therapeutic prospects A. Guenther (Giessen, Germany)
| |
Phenotypic Analysis of a Ferret Model of Cystic Fibrosis J. Engelhardt (Iowa City, Il, United States of America)
| |
Use of Airway Epithelial Cell Cultures in Inflammatory Lung Disease Research P. Hiemstra (Leiden, The Netherlands)
| |
Chronic Airway Inflammation promotes de novo Sensitization to Inhaled Allergen by Persistent Activation of Dendritic Cells L. Van Rijt (Amsterdam , Netherlands)
| |
Chronic lung disease in CF mouse models, role of macrophages, treatment with azithromycin T. Leal (Brussels, Belgium)
| |
Effects of acute and chronic LPS exposure on the inflammatory response in CF mice M. Egan (New Haven, Ct, United States of America)
| |
Procoagulant activity and signalling in fibroproliferative lung disease R. Chambers (London, United Kingdom)
| |
Lung Embryology, congenital abnormalities R. Rottier (Rotterdam, Netherlands)
| |
Noninvasive and invasive pulmonary function measurements in mice with obstructive and restrictive respiratory diseases W. Janssens (Leuven, Belgium)
| |
From Electrophysiology to Pathology D. Sheppard, (Bristol, United Kingdom)
| |
The inhibitory effect of fenretinide on the expression of inflammatory cytokines, possible molecular target of the drug and its relevance to cystic fibrosis. D. Radzioch (Montreal, Canada)
| |
Non-viral and viral gene transfer in ex vivo and in vivo lung models U. Griesenbach (London, United Kingdom)
| |
CFTR correctors and potentiators: pre-clinical studies in mouse models for CF M. Wilke (Rotterdam, Netherlands)
| |
Characterisation of a model that mimics aspects of the hyper-inflammatory response observed during an acute exacerbation of COPD. K. Banner (Horsham, United Kingdom)
| |
Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis L. Touqui (Paris, France)
| |